CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events
Item8.01 Other Events.
On March28, 2017, CRISPR Therapeutics AG ( the Company) issued a
press release reporting that the European Patent Office announced
its intention to grant a patent related to the Companys
in-licensed gene editing technology in connection with European
Patent Application No.13793997. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
Item9.01.Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not
filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press Release by CRISPR Therapeutics AG, dated March28, 2017 |
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States. CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Recent Trading Information
CRISPR THERAPEUTICS AG (NASDAQ:CRSP) closed its last trading session up +1.05 at 21.77 with 53,553 shares trading hands.